SELLAS Life Sciences Group Inc (NAS:SLS)
$ 0.98 -0.03 (-2.97%) Market Cap: 68.97 Mil Enterprise Value: 50.63 Mil PE Ratio: 0 PB Ratio: 3.92 GF Score: 39/100

Sellas Life Sciences Group Inc to Host Key Opinion Leader Webinar Transcript

Jan 31, 2023 / 01:30PM GMT
Release Date Price: $3.32 (+2.15%)
Operator

Good morning, and welcome to the SELLAS Life Sciences Group KOL event. (Operator Instructions) As a reminder, this webinar is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the event.

Before we begin, I'd like to make reference to the forward-looking statements slide on the screen.

I'd now like to turn the call over to your host, Dr. Angelos Stergiou, Founder, President and Chief Executive Officer of SELLAS Life Sciences Group.

Angelos M. Stergiou
SELLAS Life Sciences Group, Inc. - Founder, President, CEO & Director

Thank you very much, Tara, and good morning, everyone, and thank you for joining us today for our KOL webinar to discuss SELLAS's Phase III clinical trial of galinpepimut-S, or GPS, in patients with acute myeloid leukemia in second remission, the REGAL study. We're privileged to be joined by renowned hematologist-oncologist, Dr. Omer Jamy, who is a REGAL study principal investigator at the University of Alabama at Birmingham, one of the highest enrolling REGAL sites. Dr.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot